Literature DB >> 1437232

In vivo activation of macrophages by IFN-gamma to kill Entamoeba histolytica trophozoites in vitro.

E Ghadirian1, M Denis.   

Abstract

To determine the role of interferon-gamma (IFN-gamma) in the activation of macrophages to kill Entamoeba histolytica trophozoites in vitro, C57BL/6 mice were injected with various doses of recombinant IFN-gamma (rIFN-gamma) by either the intravenous, intraperitoneal or intramuscular routes. Mice were treated with doses of rIFN-gamma ranging from 10(1) to 10(5) units. Twenty hours later, peritoneal macrophages were harvested from the treated animals. Macrophage monolayers were prepared and their in vitro cytotoxic activity against a virulent strain of E. hystolytica (IP:0682:1) was determined. Amoebicidal activity was determined by counting the number of dead trophozoites by Trypan Blue exclusion in cultures containing macrophages and amoebic trophozoites which were incubated together for 4 h. Both intravenous and intraperitoneal treatment resulted in the recovery of macrophages from the peritoneal cavity which exhibited amoebicidal activity in vitro. Peritoneal macrophages harvested from mice that had been treated intraperitoneally or intravenously with rIFN-gamma, however, showed significantly more amoebicidal activity in comparison to macrophages harvested from animals treated intramuscularly. There was a dose dependent relationship between the concentration of rIFN-gamma used to activate macrophages in vivo and the number of dead trophozoites in vitro. In addition, these results confirm our previous observations that treatment in vitro with rIFN-gamma can activate murine peritoneal macrophages to kill amoebic trophozoites.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1437232     DOI: 10.1111/j.1365-3024.1992.tb00014.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  6 in total

1.  CD4+ and CD8+ T cell- and IL-17-mediated protection against Entamoeba histolytica induced by a recombinant vaccine.

Authors:  Xiaoti Guo; Lisa Barroso; David M Lyerly; William A Petri; Eric R Houpt
Journal:  Vaccine       Date:  2010-11-21       Impact factor: 3.641

2.  Oral vaccination with recombinant Yersinia enterocolitica expressing hybrid type III proteins protects gerbils from amebic liver abscess.

Authors:  Hannelore Lotter; Holger Rüssmann; Jürgen Heesemann; Egbert Tannich
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

3.  Immune markers characteristic for asymptomatically infected and diseased Entamoeba histolytica individuals and their relation to sex.

Authors:  Hannah Bernin; Claudia Marggraff; Thomas Jacobs; Norbert Brattig; Van An Le; Jörg Blessmann; Hannelore Lotter
Journal:  BMC Infect Dis       Date:  2014-11-25       Impact factor: 3.090

Review 4.  Immune Response of Amebiasis and Immune Evasion by Entamoeba histolytica.

Authors:  Kumiko Nakada-Tsukui; Tomoyoshi Nozaki
Journal:  Front Immunol       Date:  2016-05-12       Impact factor: 7.561

5.  Entamoeba histolytica Calreticulin Induces the Expression of Cytokines in Peripheral Blood Mononuclear Cells Isolated From Patients With Amebic Liver Abscess.

Authors:  Enrique Gonzalez Rivas; Cecilia Ximenez; Miriam Enriqueta Nieves-Ramirez; Patricia Moran Silva; Oswaldo Partida-Rodríguez; Eric Hernandez Hernandez; Liliana Rojas Velázquez; Angelica Serrano Vázquez; Ulises Magaña Nuñez
Journal:  Front Cell Infect Microbiol       Date:  2018-10-18       Impact factor: 5.293

Review 6.  Regulation of virulence of Entamoeba histolytica.

Authors:  Chelsea Marie; William A Petri
Journal:  Annu Rev Microbiol       Date:  2014-06-16       Impact factor: 15.500

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.